Company / Cash & Equivalents
OptimizeRx Corp Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$23.4M
FY2025
5-year range
$10.5M / $23.4M
FY2021-FY2025
Trend
+74.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $23M.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of +17.3%.
Improved from $14M to $23M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +8.7%
- 5-Year CAGR
- +17.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 74.6% year-over-year.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.4M | +74.6% |
| FY2024 | $13.4M | -3.4% |
| FY2023 | $13.9M | -23.9% |
| FY2022 | $18.2M | +73.1% |
| FY2021 | $10.5M | +0.0% |
| FY2020 | $10.5M | +18.0% |
| FY2019 | $8.9M | +74.0% |
| FY2018 | $5.1M | -27.2% |
| FY2017 | $7.0M | -14.3% |
| FY2016 | $8.2M | +138.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026